- Healthcare Roundup Apr 12Hospital M&A rebounds and health IT takes center stage at HIMSS, even as Medicaid cuts and federal data concerns raise policy risk. Research and public-health debates add nuance heading into the week.
- Healthcare Mixed Signals, Apr 11 WrapResearch advances, a rebound in hospital M&A and AI governance at payers are balancing against Medicaid cuts and data-privacy alarms. Read what to watch heading into Apr 13.
- Healthcare Roundup: Policy, FDA Hits, M&A - Apr 11Policy concerns, an FDA rejection and renewed M&A activity created a mixed picture for healthcare heading into the long weekend. Read what you should watch as markets reopen on Monday.
- Healthcare Wrap-Up Apr 10: M&A Strength, FDA SetbackToday’s healthcare tape mixed regulatory headwinds with clear momentum in deal-making and IT deployment. From an FDA rejection that rattled one biotech to $300M in DHA IT spending, here’s what you need to know.
- Healthcare Risks Top Morning Briefing - Apr 10Overnight reports raise fresh concerns about GLP-1 side effects, AI use in coverage decisions, and a major patient data leak in Hong Kong. Read what you should watch today if you follow healthcare names.
- Healthcare: Innovation Meets Policy Noise - Apr 9Researchers reported new genomics and RNA breakthroughs while biotech deal-making and an IPO plan kept capital markets engaged. Policy fights over vaccines and AI security risks add uncertainty for investors.
- Healthcare Sector Briefing - Apr 9Clinical wins for atopic dermatitis and an Asia telemedicine pilot highlight upside, while policy shifts, Medicaid staffing issues and VC disruption add caution. Here’s what to watch today.
- Healthcare: Innovation, Deals & Policy, Apr 8A wave of research advances, a big biotech financing, and policy clarity on NIH overhead dominated Healthcare today. You’ll find why these developments matter for R&D, medtech adoption, and select equities.
- Healthcare Sector News and Risks - Apr 8AI costs, privacy moves and mixed clinical signals set the tone for healthcare on Apr 8. New tech and therapy advances compete with safety concerns and regulatory pressure, so stay selective.
- Healthcare Roundup: Innovation, AI & Policy - Apr 7Today's Healthcare headlines span research breakthroughs, a new high-dose obesity launch from Novo Nordisk, rising AI tools and fresh regulatory scrutiny. Read on for market moves, implications and what you'll want to watch tomorrow.
- Healthcare: Research Wins and Policy Risks - Apr 7Breakthrough lab findings and AI adoption are driving long-term momentum in healthcare, while Medicaid cuts and a measles outbreak highlight near-term policy and public-health risks. Read what you need to watch today.
- Healthcare News: Data, Drugs and Policy - Apr 6Regulatory moves and data initiatives led today's healthcare headlines, as the FDA floated trial reforms and Amgen reported a subcutaneous Tepezza study while a small biotech faced an FDA delay. You should track forthcoming CMS guidance and industry responses to interoperability and security risks.
- Healthcare Morning Brief - Apr 6Regulatory delays and policy shifts are clashing with scientific progress and a push for better health data. Read what happened overnight and what you should watch today in healthcare.
- Healthcare Roundup Apr 5: Research, AI, HHS CutsNew antiviral research, fresh AI and interoperability talk, and a proposed 12% HHS funding cut made headlines. Heading into the holiday Monday, here's what you need to know and watch.
- Healthcare Morning Briefing - Apr 5Federal budget proposals overshadow tech and telehealth progress in healthcare. Funding cuts to HHS and NIH create uncertainty while AI, telehealth, and interoperability initiatives point to selective opportunity.
- Healthcare Policy, Tech & Research - Apr 4 WrapFunding cuts headline the weekend as the White House proposes 12% less for HHS and $5B off NIH, while telehealth, AI and new genetic and sleep research offer offsetting positives. Read on for what you should monitor heading into April 6.
- Healthcare Sector Roundup - Apr 4Federal budget proposals and NIH cut threats sit alongside telehealth expansion, AI developments from AWS, and promising vaccine research. Heading into the long weekend, the sector shows mixed signals for investors.
- Healthcare Roundup: Budget Cuts, AI & Innovation - Apr 3Federal budget proposals and tariff talk are raising policy risk, even as research breakthroughs and digital rollouts signal operational momentum. Read how telehealth, AI and new vaccine and device science could shape the sector heading into next week.
- Healthcare Wrap: Policy, Science, and Risks - Apr 3Policy and court rulings put regulatory risk back in focus while clinical advances such as TMS for PTSD and AI collaborations offer growth signals. Read what you should watch over the long weekend.
- Healthcare: Therapies, AI and Policy - Apr 2A promising prostate cancer therapy and broad AI deployments at Mount Sinai competed with policy moves that favor Medicare Advantage and fresh drug-pricing talks. You’ll want to weigh innovation against regulatory and pricing risks ahead of upcoming CMS and White House developments.
- Healthcare: Mixed Signals on Innovation and Risk - Apr 2Today’s healthcare headlines show rapid digital adoption and genomics gains alongside strained public-health capacity and access gaps. Read how AI, hospital IT and policy will shape stocks and risks.
- Healthcare Wrap-Up Apr 1: Lilly Approval, Policy NoiseEli Lilly won FDA approval for an oral obesity pill, setting up a clash with Novo Nordisk, while regulators pressed Medicare Advantage and the FDA on oversight. Research and digital-health advances add nuance for investors.
- Healthcare: Policy Headwinds, Tech Gains - Apr 1Federal funding cuts threaten community clinics even as advances in diagnostics, clinical informatics and new therapy models offer growth vectors. Today watch policy moves, NIH controversy, and a busy biotech calendar.
- Healthcare Wrap-Up, Mar 31Clinical wins and big pharma M&A led today’s headlines, while health IT, regulatory shifts and gene-editing limits temper the outlook. Read what moved the sector and what to watch next.
- Healthcare Gains Capital, Research Wins - Mar 31Big money and new science set the tone in healthcare this morning. Blackstone’s $6.3B life sciences fund, AI mental-health funding, and multiple research breakthroughs suggest momentum for research and investment.
- Healthcare Wrap-Up: AI, Data and Deals - Mar 30AI-enhanced imaging and stem-cell insights led research headlines while pharma and health systems advanced deals and deployments. Read what moved the sector today and what to watch next.
- Healthcare Roundup: Research, Policy, Industry - Mar 30Scientific advances in autism genetics and a newly identified neurodevelopmental disorder shared the spotlight with industry friction over neonatal nutrition and insurer practices. Today’s briefing highlights where research, regulation, and corporate strategy intersect for healthcare investors.
- Healthcare Wrap: AI Deals, Ethics and Burnout - Mar 29Lilly struck a large commercialization pact with AI drug developer Insilico, while CRISPR diagnostics and a new brain atlas underscore long-term scientific tailwinds. Governance and workforce issues keep risk in focus heading into Mar 30.
- Healthcare Update: Key Wins and Risks - Mar 29A major immunotherapy trial halved recurrence in stage 3 dMMR colon cancer and Otsuka paid $700M for a PTSD asset, but drug pricing talks and a VA EHR indictment add regulatory risk. Read what you need to watch heading into next week.
- Healthcare Sector Wrap - Mar 28M&A and AI progress met policy and governance headwinds as the sector heads into the long weekend. Key takeaways: Otsuka's PTSD buy, AI chemo-prediction progress, DOJ indictment tied to VA EHR.
- Healthcare Roundup - Mar 28A blend of policy, public-health data and M&A shaped the healthcare narrative over the weekend. Read what you need to know heading into the next trading week.
- Healthcare M&A, Trial Wins - Mar 27 WrapBig buyouts and an unexpected COPD trial win drove healthcare headlines today, while regulators and screening studies set watchpoints. Read what you need to know for Monday.
- Healthcare Snapshot: Key News on Mar 27Today’s healthcare briefing blends major research findings with policy shifts and funding moves. From dementia links to delirium and obesity-cancer mechanisms to rural funding and accreditation changes, here’s what you need to know.
- Healthcare Gains: FDA Approvals and M&A, Mar 26FDA approvals for Denali and Corcept, Merck's $6.7B bid for Terns, and progress on off-the-shelf CAR-T pushed healthcare headlines today. You’ll want to track near-term catalysts and regulatory noise.
- Healthcare: CDC Uncertainty, GLP-1 Guidance - Mar 26A mixed morning for healthcare: CDC leadership remains unsettled, GLP-1 guidance stresses lifestyle and mental health, and a kidney-drug stock fell despite positive data. Read what you should watch today.
- Healthcare: Gene Editing and Devices Lead - Mar 25Today brought a string of advances in gene editing, cardiac devices and imaging that suggest fresh R&D momentum across biotech and medtech. You’ll want to track catalysts ahead as markets digest competitive data and policy noise.
- Healthcare: Science, AI & Policy Watch - Mar 25A wave of scientific advances, AI funding and health IT momentum is shaping healthcare headlines today, even as public health morale and rising costs remain concerns. Read what you need to know and what to watch in markets.
- Healthcare: Policy, Deals and Research - Mar 24Regulatory moves and provider deals led headlines today as the FTC and CVS reached a proposed insulin settlement and a new CMS pilot was announced. Research and deal activity round out a mixed day for healthcare investors.
- Healthcare: Genomics, AI and Policy Risks - Mar 24Today’s healthcare headlines mix innovation with policy and safety risks. AI and genomics pilots and sustained R&D contrast with a major recall and drug-pricing uncertainty, leaving a selective opportunity set for investors.
- Healthcare Mixed Signals - Mar 23 WrapToday brought promising clinical data and AI use cases alongside regulatory and access challenges. From Apogee's 20% jump to CVS policy risk, here's what you need to know for tomorrow.
- Healthcare: Costs vs. AI Focus - Mar 23Today's healthcare headlines mix affordability and access concerns with growth in AI and operational tech. Read on for the key developments, numbers you should know, and what to watch.
- Healthcare Roundup: Research, Policy & Risks - Mar 22Research on the gut microbiome and a new sensor to prevent pressure injuries highlight innovation, while rising young-onset colorectal cancer and supply risks keep caution in play. Policy talk on Medicare Advantage adds a market angle heading into Mar 23.
- Healthcare Sector Brief - Mar 22Policy noise over automatic Medicare Advantage enrollment and a blockbuster $787M raise for AI drugmaker Earendil led the weekend headlines. Mixed signals from AI in hospitals, climate-linked kidney risk, and psychedelic therapy research mean you should be selective heading into the week.
- Healthcare Wrap — Mar 21AI and big funding led the headlines in healthcare as Earendil Labs raised $787M and AI tools show better polyp detection. Policy and supply risks remain, so stay selective heading into Monday.
- Healthcare Sector Briefing - Mar 21A mixed set of headlines heads into the long weekend: big private funding for an AI drugmaker, new Medicare Advantage enrollment talk, AI debates over coding and claims, and public-health coverage issues. Read what matters for healthcare stocks and policy heading into Monday.
- Healthcare Sector Wrap Mar 20Today’s healthcare headlines were a mixed bag: big AI-biotech funding and imaging advances countered by Roche’s SMA halt and strained hospital finances. Read what you should watch next.
- Healthcare Briefing: Key Moves - Mar 20Today’s healthcare headlines mix breakthrough science and big philanthropy with policy and workforce risks. Read what matters for drugmakers, hospitals, and medtech as markets open.
- Healthcare Moves on Obesity, AI, Approvals - Mar 19Novo Nordisk won quick FDA clearance for a high-dose Wegovy and Eli Lilly reported strong diabetes/weight results from retatrutide, while AI deals and clinical research keep investors focused on growth. Policy and access issues add complexity heading into earnings and regulatory calendars.
- Healthcare Roundup: Research & Policy - Mar 19Today's healthcare headlines mix major research wins with policy and funding pressure. From a liquid biopsy breakthrough in Africa to U.S. insurance politics, here’s what you need to know for Mar 19.
- Healthcare Mixed Signals - Mar 18A busy day in healthcare saw a major FDA approval, promising lab advances and a steep biotech selloff after an FDA rejection. You’ll want to weigh growth catalysts against regulatory and security risks.